In response to the COVID-19 pandemic, CIPO announced yesterday (March 17) that all deadlines for patents, trademarks and industrial designs falling in the period between March 16, 2020 and March 31, 2020 have been extended to April 1, 2020.

The Canadian Intellectual Property Office (the "CIPO") has released the 2020 IP Canada Report on January 26, 2021.

On November 22, 2017 the Federal Court issued a judgment granting Apotex's motion under s. 6(5)(b) of the PMNOC Regulations: Bristol-Myers Squibb et al v Apotex Inc et al, 2017 FC 1061.

Film About Pivotal Canadian Patent Case Attracting Controversy.

If this is your first time patenting something or if you are looking for a change, these 5 tips will help you make the best choice of patent professional for your technology and business

IFI Claims Patent Services reports that the US Patent and Trademark Office granted 333,530 patents in 2019, hitting an all-time high and representing an unprecedented 15% increase from 2018

The Canadian Intellectual Property Office (CIPO) remains open and in operation, but has advised that we should expect significant delays in all services.

The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.

A discussion on the strategic considerations relating to generic damages in life sciences patent litigation.

On April 28, 2017, the Supreme Court of Canada dismissed Apotex's application for leave to appeal a decision of the Federal Court of Appeal

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) ...

As previously reported, the Federal Court of Appeal dismissed Apotex's appeal from a decision holding that the claims of a patent relating to lisdexamfetamine (Shire's VYVANSE)...

Scott MacKendrick and Andrew McIntosh's article "2023's Procedural Developments in IP Litigation" was published in the Toronto Law Journal.

The September 2017 amendments to Canada's Patented Medicines Regulations introduced a new pharmaceutical patent linkage litigation scheme that more closely mirrors the US Hatch-Waxman system. This detailed comparison chart examines the similarities and differences between these two regulatory frameworks, highlighting key distinctions that remain despite the convergence.

Carmela De Luca coauthors article in Molecular Diagnosis & Therapy published by Springer Nature, "Gene Patents in Canada: Is There a New Legal Landscape?"

As we previously reported, the Canadian Intellectual Property Office (CIPO) has not issued patents since July 2, 2024. According to CIPO's updated roadmap, patent granting should resume on August 20, 2024.

The Canadian Intellectual Property Office (CIPO) recently announced that following public consultation and a pilot project, it has formalized its updated practice regarding...

In late 2019, CIPO released the IP Canada Report 2019, which details trends in patent application filings in Canada and by Canadians abroad.

Canadian intellectual property stakeholders can now learn how to spot scams, see real examples of scams, and report suspicious activity through...

In H. Lundbeck v Canada (Commissioner of Patents), 2021 FC 1394, the Court granted an application to amend a patent record to remove inventors and a co-owner.